Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decision-Reference-Cited by-同舟云学术

Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decision

Published:2021-11 Issue:11 Volume:39 Page:782.e7-782.e14
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Sayyid Rashid K.,Reed William C.,Benton John Z.,Lodh Atul,Woodruff Phillip,Lambert Joshua H.,Terris Martha K.,Wallis Christopher J.D.,Klaassen Zachary

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference26 articles.

1. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options;Sanda;J Urol,2018

2. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer;Klotz;J Clin Oncol,2015

3. Active surveillance for low-risk prostate cancer;Klotz;Curr Opin Urol,2017

4. National comprehensive cancer Network® favorable intermediate risk prostate cancer—is active surveillance appropriate?;Aghazadeh;J Urol,2018

5. Active surveillance in intermediate-risk prostate cancer;Klotz;BJU Int,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of extended core sampling with delayed intervention and pathologic outcomes for active surveillance patients;Canadian Urological Association Journal;2024-01-30

2. Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis;World Journal of Urology;2022-12-06

3. Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer;Journal of Urology;2022-08

4. No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance;Scientific Reports;2022-04-25